| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 33 | 2024 | 2478 | 2.150 |
Why?
|
| Breast | 13 | 2024 | 214 | 1.370 |
Why?
|
| Papilloma, Intraductal | 3 | 2013 | 5 | 0.820 |
Why?
|
| Carcinoma, Ductal, Breast | 6 | 2014 | 83 | 0.680 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 5 | 2014 | 63 | 0.590 |
Why?
|
| Carcinoma, Papillary | 4 | 2005 | 77 | 0.550 |
Why?
|
| Biopsy, Needle | 7 | 2011 | 229 | 0.530 |
Why?
|
| Carcinoma, Lobular | 3 | 2014 | 24 | 0.530 |
Why?
|
| Epithelial Cells | 6 | 2024 | 900 | 0.500 |
Why?
|
| Precancerous Conditions | 4 | 2023 | 283 | 0.490 |
Why?
|
| Breast Diseases | 2 | 2011 | 34 | 0.440 |
Why?
|
| Lymph Nodes | 5 | 2017 | 376 | 0.390 |
Why?
|
| Mucocele | 1 | 2011 | 9 | 0.370 |
Why?
|
| Single-Cell Analysis | 3 | 2024 | 263 | 0.360 |
Why?
|
| Carcinoma in Situ | 2 | 2008 | 67 | 0.350 |
Why?
|
| Neoplasm Invasiveness | 6 | 2021 | 605 | 0.350 |
Why?
|
| STAT5 Transcription Factor | 2 | 2022 | 89 | 0.340 |
Why?
|
| Receptor, ErbB-2 | 6 | 2019 | 501 | 0.340 |
Why?
|
| Cadherins | 2 | 2013 | 164 | 0.340 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2022 | 618 | 0.340 |
Why?
|
| Hyperplasia | 5 | 2023 | 209 | 0.330 |
Why?
|
| Head and Neck Neoplasms | 3 | 2007 | 481 | 0.300 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2018 | 43 | 0.290 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2007 | 9 | 0.290 |
Why?
|
| Female | 40 | 2024 | 65628 | 0.280 |
Why?
|
| Mammography | 4 | 2018 | 113 | 0.270 |
Why?
|
| Biomarkers, Tumor | 4 | 2019 | 1440 | 0.270 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2006 | 29 | 0.250 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2007 | 654 | 0.250 |
Why?
|
| Artifacts | 1 | 2005 | 104 | 0.240 |
Why?
|
| Thyroid Neoplasms | 4 | 2017 | 198 | 0.240 |
Why?
|
| Cell Lineage | 3 | 2024 | 341 | 0.230 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 654 | 0.230 |
Why?
|
| Mass Spectrometry | 3 | 2024 | 329 | 0.230 |
Why?
|
| Aneuploidy | 1 | 2024 | 154 | 0.220 |
Why?
|
| Stem Cells | 4 | 2018 | 701 | 0.210 |
Why?
|
| Mammary Glands, Animal | 4 | 2022 | 483 | 0.210 |
Why?
|
| Humans | 47 | 2024 | 123280 | 0.210 |
Why?
|
| Middle Aged | 16 | 2024 | 26095 | 0.210 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2023 | 73 | 0.210 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2006 | 237 | 0.210 |
Why?
|
| Calcinosis | 3 | 2013 | 170 | 0.200 |
Why?
|
| Thiazoles | 1 | 2023 | 97 | 0.200 |
Why?
|
| Diagnosis, Differential | 4 | 2018 | 1878 | 0.200 |
Why?
|
| Ultrasonography, Mammary | 4 | 2018 | 28 | 0.200 |
Why?
|
| Cell Line, Tumor | 7 | 2021 | 3286 | 0.190 |
Why?
|
| Mice | 16 | 2023 | 17555 | 0.180 |
Why?
|
| Mammary Neoplasms, Animal | 2 | 2019 | 137 | 0.180 |
Why?
|
| Receptors, Estrogen | 3 | 2018 | 791 | 0.180 |
Why?
|
| Adult | 14 | 2024 | 29091 | 0.180 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2014 | 54 | 0.170 |
Why?
|
| Wnt Proteins | 1 | 2021 | 195 | 0.170 |
Why?
|
| Gene Expression Profiling | 2 | 2024 | 1682 | 0.170 |
Why?
|
| ErbB Receptors | 1 | 2021 | 283 | 0.170 |
Why?
|
| Uridine Diphosphate Glucose Dehydrogenase | 1 | 2019 | 5 | 0.170 |
Why?
|
| DNA Copy Number Variations | 1 | 2024 | 940 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 105 | 0.160 |
Why?
|
| Codon | 1 | 2019 | 96 | 0.160 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2021 | 280 | 0.160 |
Why?
|
| Cinnamates | 1 | 2018 | 15 | 0.160 |
Why?
|
| Granulomatous Mastitis | 1 | 2018 | 6 | 0.150 |
Why?
|
| Hyaluronic Acid | 1 | 2019 | 95 | 0.150 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2018 | 106 | 0.150 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2018 | 99 | 0.150 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2019 | 70 | 0.150 |
Why?
|
| Animals | 18 | 2023 | 33850 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 3553 | 0.150 |
Why?
|
| Molecular Imaging | 1 | 2018 | 61 | 0.150 |
Why?
|
| Aged | 9 | 2014 | 19180 | 0.150 |
Why?
|
| Lymphocytes | 1 | 2019 | 402 | 0.150 |
Why?
|
| Aged, 80 and over | 7 | 2014 | 6390 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2019 | 717 | 0.140 |
Why?
|
| Indoles | 1 | 2018 | 181 | 0.140 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 322 | 0.140 |
Why?
|
| Cell Differentiation | 5 | 2018 | 1915 | 0.140 |
Why?
|
| Phyllodes Tumor | 1 | 2017 | 11 | 0.140 |
Why?
|
| Janus Kinase 2 | 1 | 2018 | 134 | 0.140 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2019 | 216 | 0.140 |
Why?
|
| Organ Specificity | 1 | 2017 | 422 | 0.130 |
Why?
|
| Nuclear Proteins | 1 | 2023 | 1268 | 0.130 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 1 | 2016 | 7 | 0.130 |
Why?
|
| Transcription Factors | 4 | 2023 | 2591 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 713 | 0.130 |
Why?
|
| Biopsy, Large-Core Needle | 2 | 2013 | 29 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2019 | 327 | 0.130 |
Why?
|
| Multimodal Imaging | 1 | 2017 | 111 | 0.130 |
Why?
|
| Signal Transduction | 5 | 2021 | 4498 | 0.130 |
Why?
|
| Lymphatic Metastasis | 4 | 2014 | 401 | 0.130 |
Why?
|
| Retrospective Studies | 6 | 2013 | 16081 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2021 | 679 | 0.120 |
Why?
|
| Extracellular Matrix | 2 | 2019 | 231 | 0.120 |
Why?
|
| Disease Progression | 5 | 2021 | 2031 | 0.120 |
Why?
|
| Lactation | 1 | 2016 | 188 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 351 | 0.120 |
Why?
|
| Thyroid Gland | 3 | 2021 | 113 | 0.120 |
Why?
|
| Parathyroidectomy | 2 | 2021 | 49 | 0.120 |
Why?
|
| Pathology, Surgical | 1 | 2014 | 19 | 0.110 |
Why?
|
| Radiography | 2 | 2013 | 822 | 0.110 |
Why?
|
| Chemokine CCL1 | 1 | 2013 | 4 | 0.110 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2013 | 59 | 0.110 |
Why?
|
| Fibroadenoma | 1 | 2013 | 9 | 0.110 |
Why?
|
| Mammary Glands, Human | 1 | 2013 | 79 | 0.100 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 5061 | 0.100 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 143 | 0.100 |
Why?
|
| Immunohistochemistry | 5 | 2007 | 1686 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1231 | 0.100 |
Why?
|
| Axilla | 2 | 2008 | 38 | 0.100 |
Why?
|
| eIF-2 Kinase | 1 | 2011 | 36 | 0.090 |
Why?
|
| Mice, Nude | 3 | 2021 | 696 | 0.090 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 504 | 0.090 |
Why?
|
| Cell Movement | 4 | 2021 | 831 | 0.090 |
Why?
|
| Neoplasms | 2 | 2017 | 2759 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 488 | 0.090 |
Why?
|
| Biopsy | 2 | 2018 | 1236 | 0.090 |
Why?
|
| Chromatin | 2 | 2024 | 554 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2010 | 9 | 0.090 |
Why?
|
| Lymphangitis | 1 | 2010 | 5 | 0.090 |
Why?
|
| Tissue Array Analysis | 2 | 2021 | 137 | 0.090 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 327 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 2588 | 0.080 |
Why?
|
| Cytodiagnosis | 1 | 2009 | 19 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 1664 | 0.080 |
Why?
|
| Neoplasm Transplantation | 2 | 2021 | 369 | 0.080 |
Why?
|
| Cells, Cultured | 3 | 2024 | 3045 | 0.080 |
Why?
|
| Granular Cell Tumor | 1 | 2008 | 3 | 0.080 |
Why?
|
| Cell Proliferation | 4 | 2018 | 2297 | 0.080 |
Why?
|
| Trastuzumab | 2 | 2019 | 131 | 0.070 |
Why?
|
| Sarcoidosis | 1 | 2008 | 61 | 0.070 |
Why?
|
| Autophagy | 1 | 2011 | 389 | 0.070 |
Why?
|
| Keratins | 3 | 2019 | 55 | 0.070 |
Why?
|
| Carcinoma | 1 | 2010 | 278 | 0.070 |
Why?
|
| Neoplasm, Residual | 1 | 2007 | 121 | 0.070 |
Why?
|
| Prognosis | 4 | 2019 | 4518 | 0.070 |
Why?
|
| Pattern Recognition, Automated | 1 | 2007 | 48 | 0.070 |
Why?
|
| Mice, Transgenic | 3 | 2019 | 2398 | 0.070 |
Why?
|
| Conization | 1 | 2006 | 4 | 0.070 |
Why?
|
| Models, Anatomic | 1 | 2007 | 98 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2011 | 796 | 0.060 |
Why?
|
| Endothelial Cells | 2 | 2023 | 526 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 884 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2007 | 220 | 0.060 |
Why?
|
| Tamoxifen | 2 | 2018 | 363 | 0.060 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2004 | 8 | 0.060 |
Why?
|
| Clone Cells | 1 | 2024 | 166 | 0.060 |
Why?
|
| Lung Neoplasms | 2 | 2013 | 1591 | 0.060 |
Why?
|
| Mastectomy | 1 | 2024 | 64 | 0.060 |
Why?
|
| Margins of Excision | 1 | 2024 | 51 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2005 | 420 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2007 | 243 | 0.050 |
Why?
|
| Neoplasm Grading | 2 | 2014 | 266 | 0.050 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2023 | 38 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2005 | 862 | 0.050 |
Why?
|
| Gene Expression | 1 | 2007 | 1566 | 0.050 |
Why?
|
| Immunity | 1 | 2023 | 179 | 0.050 |
Why?
|
| Models, Biological | 1 | 2007 | 1453 | 0.050 |
Why?
|
| Cellular Reprogramming | 1 | 2023 | 115 | 0.050 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2023 | 295 | 0.050 |
Why?
|
| Phosphorylation | 3 | 2013 | 1613 | 0.050 |
Why?
|
| RNA Interference | 2 | 2013 | 499 | 0.040 |
Why?
|
| Ubiquitin | 1 | 2021 | 141 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 1211 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2021 | 196 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2005 | 1521 | 0.040 |
Why?
|
| Risk Factors | 2 | 2018 | 10033 | 0.040 |
Why?
|
| Uridine Diphosphate Glucuronic Acid | 1 | 2019 | 6 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2021 | 967 | 0.040 |
Why?
|
| Chorioallantoic Membrane | 1 | 2019 | 12 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 236 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 862 | 0.040 |
Why?
|
| Chick Embryo | 1 | 2019 | 131 | 0.040 |
Why?
|
| PPAR gamma | 1 | 2019 | 91 | 0.040 |
Why?
|
| Leukocyte Common Antigens | 1 | 2019 | 89 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2021 | 738 | 0.040 |
Why?
|
| Wnt1 Protein | 1 | 2018 | 71 | 0.040 |
Why?
|
| Pimozide | 1 | 2018 | 6 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 1008 | 0.040 |
Why?
|
| Hyperprolactinemia | 1 | 2018 | 17 | 0.040 |
Why?
|
| Cell Separation | 1 | 2019 | 230 | 0.040 |
Why?
|
| Protein Array Analysis | 1 | 2018 | 101 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2018 | 221 | 0.040 |
Why?
|
| Heterografts | 1 | 2018 | 178 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 353 | 0.040 |
Why?
|
| Age Factors | 1 | 2024 | 2808 | 0.040 |
Why?
|
| Risperidone | 1 | 2018 | 60 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2019 | 570 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 4299 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 2 | 2013 | 295 | 0.040 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2019 | 244 | 0.040 |
Why?
|
| Glycerophospholipids | 1 | 2017 | 7 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2017 | 103 | 0.030 |
Why?
|
| Glycolipids | 1 | 2017 | 33 | 0.030 |
Why?
|
| Sphingolipids | 1 | 2017 | 28 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 142 | 0.030 |
Why?
|
| Glucose Transporter Type 1 | 2 | 2006 | 24 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2017 | 148 | 0.030 |
Why?
|
| Estradiol | 1 | 2018 | 544 | 0.030 |
Why?
|
| Estrogens | 1 | 2018 | 512 | 0.030 |
Why?
|
| Quinazolines | 1 | 2017 | 176 | 0.030 |
Why?
|
| Phenotype | 1 | 2005 | 4225 | 0.030 |
Why?
|
| Young Adult | 1 | 2009 | 8870 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 1474 | 0.030 |
Why?
|
| Macrophages | 1 | 2019 | 604 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2017 | 338 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2018 | 867 | 0.030 |
Why?
|
| Antipsychotic Agents | 1 | 2018 | 373 | 0.030 |
Why?
|
| Mutation | 2 | 2019 | 5765 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2017 | 577 | 0.030 |
Why?
|
| Phosphoproteins | 2 | 2006 | 400 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2014 | 89 | 0.030 |
Why?
|
| Diphenylamine | 1 | 2013 | 4 | 0.030 |
Why?
|
| Receptors, CCR8 | 1 | 2013 | 1 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2013 | 23 | 0.030 |
Why?
|
| Chemotactic Factors | 1 | 2013 | 17 | 0.030 |
Why?
|
| Endothelium, Lymphatic | 1 | 2013 | 10 | 0.030 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2013 | 39 | 0.030 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2013 | 40 | 0.030 |
Why?
|
| Time-Lapse Imaging | 1 | 2013 | 11 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2013 | 58 | 0.030 |
Why?
|
| Lymphatic Vessels | 1 | 2013 | 37 | 0.030 |
Why?
|
| Chemotaxis | 1 | 2013 | 55 | 0.030 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2013 | 38 | 0.030 |
Why?
|
| Palliative Care | 1 | 2017 | 428 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2013 | 112 | 0.030 |
Why?
|
| Side-Population Cells | 1 | 2013 | 11 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2006 | 470 | 0.030 |
Why?
|
| CD24 Antigen | 1 | 2013 | 29 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 495 | 0.030 |
Why?
|
| Benzamides | 1 | 2013 | 105 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2013 | 66 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 1754 | 0.030 |
Why?
|
| Histones | 2 | 2006 | 528 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2013 | 254 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2013 | 227 | 0.020 |
Why?
|
| Trans-Activators | 2 | 2006 | 808 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 233 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 1063 | 0.020 |
Why?
|
| Inflammation | 1 | 2019 | 1404 | 0.020 |
Why?
|
| Adolescent | 1 | 2009 | 19126 | 0.020 |
Why?
|
| Apoptosis | 1 | 2018 | 1787 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 667 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 254 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2011 | 314 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2011 | 318 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2014 | 528 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2013 | 373 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2011 | 286 | 0.020 |
Why?
|
| Lymphangiogenesis | 1 | 2010 | 18 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2011 | 330 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 619 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 392 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2011 | 244 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 454 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2011 | 452 | 0.020 |
Why?
|
| Male | 3 | 2018 | 60345 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 805 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2006 | 2053 | 0.020 |
Why?
|
| Cytokines | 1 | 2013 | 1266 | 0.020 |
Why?
|
| Parathyroid Glands | 1 | 2007 | 28 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2011 | 884 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2007 | 297 | 0.020 |
Why?
|
| Melanoma | 1 | 2013 | 827 | 0.020 |
Why?
|
| Cell Line | 1 | 2011 | 2771 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2006 | 145 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 1871 | 0.020 |
Why?
|
| Hypoxia | 1 | 2006 | 248 | 0.010 |
Why?
|
| Reoperation | 1 | 2007 | 819 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2007 | 631 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2006 | 618 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2011 | 3734 | 0.010 |
Why?
|
| Pregnancy | 1 | 2016 | 7129 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2008 | 12176 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 2019 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 866 | 0.010 |
Why?
|